

April 1, 2026

Matthew Angel
Chief Executive Officer
Tempest Therapeutics, Inc.
200 Sierra Point Parkway, Suite 400
Brisbane, CA 94005

Re: Tempest Therapeutics, Inc.
Registration Statement on Form S-3
Filed March 30, 2026
File No. 333-294740

Dear Matthew Angel:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Chris Edwards at 202-551-6761 with any questions.

Sincerely,

Division of

Office of Life

Corporation Finance

Sciences

cc: Asa M. Henin